248 related articles for article (PubMed ID: 24019132)
1. Nanoscale markers of esophageal field carcinogenesis: potential implications for esophageal cancer screening.
Konda VJ; Cherkezyan L; Subramanian H; Wroblewski K; Damania D; Becker V; Gonzalez MH; Koons A; Goldberg M; Ferguson MK; Waxman I; Roy HK; Backman V
Endoscopy; 2013 Dec; 45(12):983-8. PubMed ID: 24019132
[TBL] [Abstract][Full Text] [Related]
2. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
[TBL] [Abstract][Full Text] [Related]
3. Structural alterations of the mucosa stroma in the Barrett's esophagus metaplasia-dysplasia-adenocarcinoma sequence.
Bobryshev YV; Killingsworth MC; Lord RV
J Gastroenterol Hepatol; 2012 Sep; 27(9):1498-504. PubMed ID: 22591183
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil-Lymphocyte Ratio as a Marker of Progression from Non-Dysplastic Barrett's Esophagus to Esophageal Adenocarcinoma: a Cross-Sectional Retrospective Study.
Campos VJ; Mazzini GS; Juchem JF; Gurski RR
J Gastrointest Surg; 2020 Jan; 24(1):8-18. PubMed ID: 31745889
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA profile in neosquamous esophageal mucosa following ablation of Barrett's esophagus.
Sreedharan L; Mayne GC; Watson DI; Bright T; Lord RV; Ansar A; Wang T; Kist J; Astill DS; Hussey DJ
World J Gastroenterol; 2017 Aug; 23(30):5508-5518. PubMed ID: 28852310
[TBL] [Abstract][Full Text] [Related]
6. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA expression differentiates squamous epithelium from Barrett's esophagus and esophageal cancer.
Garman KS; Owzar K; Hauser ER; Westfall K; Anderson BR; Souza RF; Diehl AM; Provenzale D; Shaheen NJ
Dig Dis Sci; 2013 Nov; 58(11):3178-88. PubMed ID: 23925817
[TBL] [Abstract][Full Text] [Related]
8. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
[TBL] [Abstract][Full Text] [Related]
9. DCLK1 is detectable in plasma of patients with Barrett's esophagus and esophageal adenocarcinoma.
Whorton J; Sureban SM; May R; Qu D; Lightfoot SA; Madhoun M; Johnson M; Tierney WM; Maple JT; Vega KJ; Houchen CW
Dig Dis Sci; 2015 Feb; 60(2):509-13. PubMed ID: 25283374
[TBL] [Abstract][Full Text] [Related]
10. Dysplasia in Barrett's esophagus. A clinicopathologic study of six patients.
Lee RG
Am J Surg Pathol; 1985 Dec; 9(12):845-52. PubMed ID: 2416226
[TBL] [Abstract][Full Text] [Related]
11. Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett's Esophagus-Related Neoplasia: A Feasibility Study.
Everson M; Magee C; Alzoubaidi D; Brogden S; Graham D; Lovat LB; Novelli M; Haidry R
Dig Dis Sci; 2019 Oct; 64(10):2815-2822. PubMed ID: 30982210
[TBL] [Abstract][Full Text] [Related]
12. Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas.
Corley DA; Mehtani K; Quesenberry C; Zhao W; de Boer J; Weiss NS
Gastroenterology; 2013 Aug; 145(2):312-9.e1. PubMed ID: 23673354
[TBL] [Abstract][Full Text] [Related]
13. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma.
Samuels TL; Altman KW; Gould JC; Kindel T; Bosler M; MacKinnon A; Hagen CE; Johnston N
Laryngoscope; 2019 Dec; 129(12):2687-2695. PubMed ID: 31046139
[TBL] [Abstract][Full Text] [Related]
14. Gastric metaplasia of the proximal esophagus associated with esophageal adenocarcinoma and Barrett's esophagus: what is the connection? Inlet patch revisited.
Malhi-Chowla N; Ringley RK; Wolfsen HC
Dig Dis; 2000; 18(3):183-5. PubMed ID: 11279338
[TBL] [Abstract][Full Text] [Related]
15. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
[TBL] [Abstract][Full Text] [Related]
16. Yield of Repeat Endoscopy in Barrett's Esophagus with No Dysplasia and Low-Grade Dysplasia: A Population-Based Study.
Visrodia K; Iyer PG; Schleck CD; Zinsmeister AR; Katzka DA
Dig Dis Sci; 2016 Jan; 61(1):158-67. PubMed ID: 25956705
[TBL] [Abstract][Full Text] [Related]
17. Correlation of ultrastructural aberrations with dysplasia and flow cytometric abnormalities in Barrett's epithelium.
Levine DS; Reid BJ; Haggitt RC; Rubin CE; Rabinovitch PS
Gastroenterology; 1989 Feb; 96(2 Pt 1):355-67. PubMed ID: 2910757
[TBL] [Abstract][Full Text] [Related]
18. Surveillance in Barrett's esophagus: an audit of practice.
Ajumobi A; Bahjri K; Jackson C; Griffin R
Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
[TBL] [Abstract][Full Text] [Related]
19. Endoscopic therapy of esophageal premalignancy and early malignancy.
Nealis TB; Washington K; Keswani RN
J Natl Compr Canc Netw; 2011 Aug; 9(8):890-9. PubMed ID: 21900219
[TBL] [Abstract][Full Text] [Related]
20. Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma.
Rizk NP; Servais EL; Tang LH; Sima CS; Gerdes H; Fleisher M; Rusch VW; Adusumilli PS
Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):482-6. PubMed ID: 22237988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]